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Abstract 
Objective: Astrocyte damage mediated by anti-aquaporin-4 antibodies plays a central 
role in the pathogenesis of neuromyelitis optica (NMO), which presumably requires 
preceding blood–brain barrier (BBB) disruption. Although it is well known that matrix 
metalloproteinases (MMPs) contribute to BBB disruption in multiple sclerosis (MS), 
the mechanisms responsible for the breakdown of the BBB in NMO are unclear.  
To study whether the changes in cerebrospinal fluid (CSF) and serum levels of MMPs, 
tissue inhibitors of metalloproteinases (TIMPs) and cytokines are associated with BBB 
disruption in NMO. 
 
Methods: CSF and serum samples were obtained from 29 patients with NMO (19 with 
NMO and 10 anti-aquaporin-4 antibody-positive NMO spectrum disorder), 29 with 
relapsing-remitting multiple sclerosis (MS), and 27 with other neurological disorders 
(17 with non-inflammatory and 10 with inflammatory neurological disorders). We 
measured the concentrations of 27 bioactive substances, including 9 MMPs, 4 TIMPs, 
and 14 cytokines, using a multiplex assay. We performed immunohistochemistry for 
MMP-2 and TIMP-1 expression on post-mortem brain tissues from patients with NMO. 
 
Results: In CSF but not serum samples, MMP-2, TIMP-1, interleukin-6 (IL-6) levels, 
and the MMP-2/TIMP-2 ratio were significantly elevated in patients with NMO. In the 
NMO group, the CSF/serum albumin ratio (a measure of BBB breakdown) revealed 
the highest correlation with CSF MMP-2 levels, which correlated with CSF IL-6 levels. 
Immunohistochemistry revealed MMP-2- and TIMP-1-positive cells surrounding the 
vessels in NMO lesions. 
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Conclusions: Increased CSF MMP-2 levels, likely enhanced by IL-6 signaling, may 
disrupt BBB from outside of the vessels and may enable serum anti-AQP4- antibodies 
to migrate to CNS across BBB in patients with NMO. 
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Introduction 
Neuromyelitis optica (NMO) is an inflammatory demyelinating disease of the central 
nervous system (CNS), which is characterized by optic neuritis and longitudinally 
extensive myelitis.1, 2 NMO-IgG was discovered in the sera of NMO patients and is 
recognized as a specific biomarker of NMO.3 It has been revealed that this antibody 
targets aquaporin-4 (AQP4), a water channel protein localized at astrocytic foot 
processes, and is a key molecule in the pathogenesis of NMO.4 Mechanisms for the 
disruption of the blood–brain barrier (BBB) and invasion of the anti-AQP4 antibody in 
the CNS remain unknown, although the cerebrospinal fluid (CSF)/serum albumin ratio 
(Q albumin, Qalb), a measure of BBB breakdown, is elevated in NMO.5 
Several studies have shown that inflammatory cytokines and matrix 
metalloproteinases (MMPs) induce BBB disruption.6-8 The MMPs are a family of 
zinc-containing and Ca2+-requiring endopeptidases, mediating the degradation and 
remodeling of extracellular matrix (ECM) components, including fibronectin, laminin, 
elastin, collagen IV, and proteoglycans, in pathological and physiological processes 
such as tissue remodeling and wound healing.9 Laminin, fibronectin, and collagen IV 
are reported to be the major ECM components of brain capillaries;10 hence, MMPs, 
including MMP-2, -3, and -9, which are capable of degrading collagen IV, can be 
involved in BBB disruption.6  
The activity of MMPs is regulated by various factors, including MMP gene 
expression, others MMPs, and tissue inhibitors of metalloproteinases (TIMPs). 
Moreover, MMP gene expression is regulated by Th-17-related cytokines such as 
tumor necrosis (TNF)-α, interleukin (IL)-1β, IL-6, and IL-17. 6, 11-13 Therefore, MMPs, 
TIMPs, and Th-17-related cytokines play an important role in BBB function. 
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Additionally, these molecules are related to BBB disruption and the transmigration of 
inflammatory cells in MS.14, 15 
In this study, we aimed to elucidate the role of MMPs in disruption of BBB, and to 
investigate the association of MMPs with TIMPs and Th-17-related cytokines in NMO. 
 
Methods 
Patients 
Patients enrolled in this study were seen at the Chiba University Hospital between 
2000 and 2014. Twenty-nine patients had relapsing-remitting MS (6 of which were 
men), fulfi lling the 2010 revisions of the McDonald criteria,16 and 29 patients had NMO, 
including 19 patients fulfilling the 2006 Wingerchuk NMO criteria17 and 10 anti-AQP4 
antibody-positive NMO spectrum disorder (NMOSD) patients fulfilling the 2015 
Wingerchuk criteria.18 Clinical relapses were defined as the outbreak of any new 
neurological symptoms or the worsening of previous symptoms associated with a 
clinical sign persisting longer than 24 h in the absence of fever, in patients who were  
previously clinically stable for at least 30 day. Twenty-seven patients had other 
neurological diseases (ONDs), including 17 with non-inflammatory neurological 
disorders (5 Parkinson's disease, 1 corticobasal degeneration,1 progressive 
supranuclear palsy, 3 multiple system atrophy, 1 spinocerebellar degeneration, and 6 
amyotrophic lateral sclerosis) and 10 with inflammatory neurological disorders (4 
Neuro-Behçet disease, 4 neurosarcoidosis, and 2 CNS lupus). 
We reviewed the gender, age, disease duration, Krutzke’s expanded disability 
status scale (EDSS)19 score, presence of longitudinally extensive (≥3 vertebral 
segment) spinal cord lesions (LESCL), serum anti-AQP4 antibody positivity,20 
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oligoclonal IgG bands positivity, IgG index, whether the brain magnetic resonance 
imaging (MRI) fulfilled the Paty's MRI criteria,21 positive gadolinium-enhancing brain 
and spinal cord lesions on MRI, and whether patients had received any 
immunomodulating therapy at the time of sample collection, such as interferon (INF)-β, 
fingolimod, continuous oral prednisolone, or azathioprine. 
This study was approved by the Ethics Committee of the Chiba University School 
of Medicine. All the participants gave informed consent for their participation in this 
study. 
 
CSF and Serum Sampling  
CSF and serum samples were obtained from NMO and MS patients at clinical relapse, 
within 50 days of the relapse onset before treatment for relapse. All samples were 
stored at -80 ºC until analysis.  
 
MMP, TIMP, and cytokine concentrations  
The concentration of 9 MMPs (MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, 
MMP-10, MMP-12, and MMP-13), 4 TIMPs (TIMP-1, TIMP2, TIMP-3 and TIMP-4), 
and 14 cytokines (IL-1β, IL-4, IL-6, IL-10, IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-25, 
IL-31, IL-33, IFN-γ,  and TNF-α) in the CSF were measured using the Bio-Plex 
ProTM® magnetic bead-based multiplex immunoassay (Bio-Rad, Hercules, CA, USA). 
The fluorescence intensity from the immunoassay was acquired and analyzed using 
the Bio-PlexTM 200 System (software version 6.1; Bio-Rad Laboratories). MMPs, 
TIMPs, and cytokines in the CSF that were significantly different between NMO, MS, 
and OND patient groups were also measured in the sera of these three groups. For 
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statistical analysis, the concentrations below the lower limit of detection were replaced 
by a value equivalent to half the lower limit of detection. 
 
CSF/serum ratio of elevated MMPs, TIMPs, and cytokines in the NMO patients 
The CSF/serum ratio of elevated MMPs, TIMPs, and cytokines in NMO patients was 
calculated from the measured concentrations, if those levels were directly measured 
without replacement. 
 
Magnetic resonance imaging (MRI) 
MRI scans were taken exclusively at symptom onset and within 60 days of onset. A 
1.5-T MRI scanner was used to perform brain and spinal cord MRI. Lesions showing 
gadolinium enhancement on T1-weighted images were defined as active lesions. 
 
Correlation of CSF bioactive substances with Qalb or clinical, laboratory, and 
radiological findings in NMO patients 
We first analyzed the correlations between CSF bioactive substances, including 
MMPs, TIMPs, and cytokines, and Qalb to investigate the association between BBB 
permeability and these substances in NMO patients. Secondly, we identified CSF 
bioactive substances that were significantly different between NMO and MS patients 
or between NMO and OND patients. We then analyzed the correlation between the 
identified bioactive substances and the clinical, laboratory, and radiological findings of 
the NMO patients, including the EDSS, CSF cell count, CSF protein concentration, 
IgG index, and MRI findings. 
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Immunohistochemical detection of MMP-2 and TIMP-1with NMO  
We performed immunohistochemical analysis for AQP4, MMP-2, and TIMP-1 on 
post-mortem brain tissues obtained from two patients with NMO (69- and 44-year-old 
females with disease durations of 12 and 4 years, respectively). The primary 
antibodies used were the anti-AQP4 rabbit antibody (Sigma-Aldrich, dilution 1:100, 
USA), anti-MMP-2 mouse antibody (clone: 17B11, Leica Biosystems, dilution 1:200, 
Germany), and anti-TIMP-1 monoclonal antibody (clone: 6F6a, Leica Biosystems, 
dilution 1:1000, Germany). 
 
Statistical analysis  
The Mann–Whitney U test with the Holm adjustment and Fisher's exact probability test 
were conducted to compare groups. Spearman’s rank correlation analysis was used 
to assess correlation. A P value below 0.05 was considered statistically significant. All 
statistical analyses were performed using SPSS statistical software, version 16.0J 
(SPSS Japan Inc, Tokyo, Japan). 
 
Results 
Clinical characteristics of the patients  
The demographic and clinical characteristics, laboratory findings, MRI findings, and 
treatments of the patients with NMO and MS are shown in Table 1. The sex ratio, age, 
disease duration, CSF cell count, CSF protein concentration, IgG index, the rate of 
patients whose MRI fulfill the Paty’s criteria,20 and the rate of patients with 
gadolinium-enhancing lesions on MRI, were each similar between the NMO and MS 
groups. EDSS scores, positivity for anti-AQP4 antibodies, Qalb, negativity for 
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oligoclonal IgG bands, positivity for having LESCL on previous spinal cord MRI, and 
the frequency of patients with any immunomodulating therapy and continuous oral 
prednisolone therapy were higher in the NMO group than in the MS group.   
 
CSF and serum MMP, TIMP, and cytokine profiles 
CSF and serum MMP, TIMP, and cytokine profiles of NMO, MS, and ONDs are 
presented in Table 2. Of the MMPs, TIMPs, and cytokines, significant differences 
between any two of the three patient groups are shown in Figure 1. CSF MMP-2, 
TIMP-1, and IL-6 levels were significantly higher in NMO patients than in both MS and 
OND patients. CSF IL-17A levels were significantly higher in MS patients than in both 
NMO and OND patients, and CSF MMP-13 levels were significantly higher in MS 
patients than in OND patients (Figure 1). The CSF MMP-2/TIMP-2 ratio was 
significantly elevated in NMO patients compared with MS and OND patients. There 
were no significant differences in other CSF MMPs, TIMPs and cytokines among the 
three groups (Table 2). CSF MMPs, TIMPs and cytokines, significant differences 
between any two of the three groups, as well as MMP-9, were also measured in the 
sera of the three groups of patients; however, no significant differences in any of these 
factors were observed between any of the groups (Table 2). 
 
CSF/serum ratios of MMP-2, TIMP-1, and IL-6 in NMO patients 
The CSF/serum ratios of MMP-2, TIMP-1, and IL-6 in the NMO patient group are 
shown in Figure 2. The median CSF/serum ratios of MMP-2 and IL-6 were over 1.0, 
indicating these substances were predominantly produced in the CNS. The median 
ratio values for MMP-2, TIMP-1, and IL-6 were 1.25 (interquartile range [IQR]: 0.95), 
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0.21 (IQR: 0.17), and 1.47 (IQR: 1.12), respectively.  
 
MRI findings  
MRI scans performed at clinical onset were available for 23 of 29 NMO patients and 
for 21 of 29 MS patients. Active lesions with gadolinium enhancement on MRI were 
observed in 11 of the 23 NMO patients, and in 12 of the 21 MS patients, although the 
frequency was not significantly different between NMO and MS groups. 
 
Correlation of CSF bioactive substances with Qalb and with MRI, clinical, laboratory, 
and radiological findings in NMO patients 
Qalb was correlated with CSF levels of MMP-2, MMP-3, MMP-7, MMP-10, TIMP-1, 
IL-6, IL-10, and TNF-α in NMO patients (Table 3). CSF bioactive substances that were 
significantly different either between NMO and MS or between NMO and OND 
patients, and which were also significantly correlated with Qalb, included only MMP-2 
(ρ = 0.753; P < 0.0001), TIMP-1 (ρ = 0.604; P = 0.001), and IL-6 (ρ = 0.450; P = 0.021) 
(Figure 3A–C). CSF MMP-2 showed the highest correlation with Qalb, we analyzed 
the association of MMP-2 with other bioactive substances and with clinical, laboratory, 
and radiological findings. CSF MMP-2 levels showed correlation with CSF TIMP-1 (ρ 
= 0.669; P < 0.0001), IL-6 levels (ρ = 0.547; P = 0.002) (Figure 3D and E), CSF 
proteins (ρ = 0.751; P < 0.0001), the IgG index (ρ = 0.598; P = 0.001), and CSF cell 
counts (ρ = 0.493; P = 0.008; Figure 3F–H), but not with other clinical, laboratory, or 
radiological findings. Furthermore, CSF IL-6 was correlated with TIMP-1 (ρ = 0.691; P 
< 0.0001) 
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Immunohistochemical analysis 
In post-mortem brain tissues, MMP-2 (B, E) and TIMP-1 (C, F) weakly positive cells 
were suspected to be macrophages and were observed around the vessels in NMO 
lesions (Figure 4) where AQP4 was lost (A, D).  
 
Discussion 
Our results show that CSF levels of MMP-2, TIMP-1 and IL-6 were significantly 
elevated in NMO patients and that CSF MMP-2 levels are significantly correlated with 
Qalb and IL-6 levels in NMO patients. Taken together, our findings suggest that 
upregulated MMP-2 is associated with the breakdown of BBB. 
Few studies have demonstrated the role of MMP on BBB disruption in NMO 
pathogenesis. Serum MMP-9 levels and CSF TIMP-1 levels were significantly 
elevated, and serum MMP-9 levels were significantly correlated with Qalb in patients 
with NMO. 22 Moreover, sera from patients with NMO significantly increased the 
autocrine MMP-2/9 secretion in cultured human brain microvascular endothelial cells 
and decreased BBB function, which could be reversed by a broad inhibitor of MMPs 
(including MMP-2 and MMP-9). 23 Although these findings suggest that MMPs are 
involved in BBB disruption in patients with NMO, CSF MMP-2 is not examined. In our 
study, CSF MMP-2 levels are elevated in CSF but not in the serum of patients with 
NMO and are strongly correlated with Qalb. Moreover, the CSF/serum MMP-2 ratio 
suggests that MMP-2 is predominantly produced in CNS. Immunocytochemistry 
revealed MMP-2 positive cells, probable macrophages, around the vessels. We 
suggest that elevated CSF MMP-2 levels reached the ECM composing BBB from 
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outside of the blood vessels to increase BBB permeability. Recent studies have shown 
that pericytes, the outermost component of BBB, express MMP-2, -3, and -9 receptors 
and play an important role in neurovascular function, including BBB formation.24 
Pieper et al. reported that pericytes support the transmigration of neutrophi ls, and a 
specific inhibitor of MMP-2 and MMP-9, which significantly decreases the effect of 
transmigration from outside the cerebral small vessel in NMO, may first act on 
pericytes.25 
Several studies have demonstrated that a regulatory pathway for MMP and TIMP 
expressions is mediated by IL-6. Elevated IL-6 levels were significantly correlated with 
mRNA and protein levels of MMP-2/9 and TIMP-1. 11, 12, 26, 27 We observed similar 
findings in CSF in NMO patients. Therefore, CSF IL-6 may induce MMP-2 and TIMP-1 
production in CNS. 
The elevation of CSF MMP-2, TIMP-1, and IL-6 levels seen in NMO is not seen in 
MS. BBB disruption is important in the pathogeneses of NMO and MS, but the 
underlying mechanism of BBB disruption may be different between these two 
disorders. This difference may be caused by high CSF levels of IL-6, which could 
induce MMP-2 and TIMP-1 production in the CNS. Therefore, IL-6 could potentially be 
used as a biomarker to differentiate NMO from MS.  
Furthermore, other factors could regulate MMP-2 activity. Plasmin can activate 
MMP-2, while plasmin inhibitors and anti-urokinase plasminogen activator antibodies 
can inhibit pro-MMP-2 activation. 28 Angiotensin II (ANG II) induced MMP-2 release 
and reduced TIMP-2 selection. Moreover, the ANG II receptor blocker (ARB) 
prevented these effects. 29 Hence, a plasmin inhibitor and ARB could be novel 
therapeutic agents in patients with NMO via MMP-2 suppression.  
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Our study has several limitations. First, we were unable to clarify which cells 
produce MMP-2, TIMP-1, and IL-6 and sufficiently define the order of production of 
these three bioactive substances. Further studies, perhaps using in vitro BBB models 
of cultured cells, to clarify which cells produce these bioactive substances, and in 
what order, are therefore required. Second, generally, activated MMPs are derived 
from the activation of pro-MMPs. Our assays detect not only the activated MMP form 
but also the inactivated pro-forms; thus, further analysis specifically of activated 
MMPs using zymography could be beneficial for the understanding of the association 
between BBB and MMPs. 
In conclusion, our study suggests that CSF MMP-2 plays an important role in the 
disruption of BBB in NMO and that elevated CSF MMP-2 may be induced by IL-6 
signaling. MMP-2 may be a novel therapeutic target for NMO. 
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Figures&Tables  
Figure 1 CSF MMP, TIMP, and cytokine concentrations in NMO, MS, and OND 
patients 
 
Concentrations of matrix metalloproteinases (MMPs), tissue inhibitors of 
metalloproteinase (TIMPs), and cytokines in the cerebrospinal fluid (CSF) of 29 
neuromyelitis optica (NMO) patients, 29 multiple sclerosis (MS) patients, and 27 
patients with other neurological disorders (ONDs). Dashed lines indicate the lower 
limit of detection (L.L.D.).  
*Statistically significant differences even after multiple comparison adjustment. 
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Figure 2 
CSF/serum ratios for MMP-2, TIMP-1, and IL-6 in NMO patients 
 
  The median CSF/serum ratios of MMP-2 and IL-6 were over 1.0, which indicates 
they were dominantly produced in the central nervous system. The median ratio 
values for MMP-2, TIMP-1, and IL-6 were 1.25 (interquartile range [IQR]: 0.95), 0.21 
(IQR: 0.17), and 1.47 (IQR: 1.12), respectively.  
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Figure 3 Correlations between CSF /serum albumin ratios (Qalb) and CSF bioactive 
substances, including MMPs, TIMPs, and cytokines  
 
Correlations were tested between CSF MMP-2 and other CSF MMPs, TIMPs, and 
cytokines levels (D, E), and between CSF MMP-2 and other CSF parameters (F–H) in 
NMO patients. Only CSF levels of MMP-2, TIMP-1, and IL-6 were significantly 
correlated with Qalb (A–C). CSF MMP-2 levels showed significant correlation with 
CSF levels of TIMP-1, IL-6, CSF proteins, IgG index, and CSF cell counts (D–H). 
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Figure 4 Immunohistochemical assessment of MMP-2 and TIMP-1 on post-mortem 
brain tissues from two NMO patients 
  
A post-mortem neuropathological study was performed with two NMO patients (pt1 
and pt2) using the brainstem (pt1 and pt2) tissues. We performed 
immunohistochemistry for AQP4 (A, D), MMP-2 (B, E), and TIMP-1 (C, F). MMP-2 
weakly positive and TIMP-1-positive large cells, suspected to be macrophages, were 
detected around the vasculature in the NMO lesions where AQP4 was lost (A, D).  
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Table 1. Demographic and clinical characteristics, laboratory and MRI findings, 
and treatments in Patients with NMO and MS. 
Clinical Characteristics 
aNMO 
(n = 29) 
MS 
(n = 29) 
P value 
Demographic and clinical 
characteristics 
   
Men:women 2:27 6:23 0.12  
Age, year; median (IQR) 52 (20) 36 (12) 0.15  
Disease duration, month; 
median (IQR)  
65 (154) 49 (124) 0.31  
EDSS; median (IQR) 6.0 (3) 2.5 (2) 0.001  
Laboratory and MRI findings 
   
Positive aquaporin-4 antibody 24/29 (83%) 0/29 (0%) <0.001 
CSF cell count (IQR) 8 (12.0) 11 (23.5) 0.44  
CSF protein concentration (IQR) 36 (28.0) 32 (8.5) 0.17  
Qalb (IQR) 60.8 (51.9) 44.1 (13.3) <0.001 
IgG index (IQR) 0.6 (0.2) 0.7 (0.4) 0.06  
Positive oligoclonal IgG bands 7/26 (27%) 16/27 (59%) 0.01  
Fulfilling Paty's MRI criteria 19/29 (66%) 22/29 (76%) 0.28  
 ≥3 vertebral segment spinal 
cord lesion 
22/29 (76%) 2/29 (7%) <0.001 
Positive Gd-enhancing brain 
lesion 
12/24 (50%) 12/21 (57%) 0.63  
Treatments (Immunomodulating 
therapy) 
   
Any treatment 14/29 (48%) 2/29 (7%) 0.001  
Interferon-β 1/29 (3%) 2/29 (7%) 0.55  
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Fingolimod 0/29 (0%) 0/29 (0%) - 
Continuous oral prednisolone 14/29 (48%) 0/29 (0%) <0.001 
Azathioprine 1/29 (3%) 0/29 (0%) 0.36  
aCSF, cerebrospinal fluid; EDSS, Krutzke's expanded disability status scale; Gd, 
gadolinium; IQR, interquartile range; 
MRI, magnetic resonance imaging; MS, multiple sclerosis; NMO, neuromyelitis optica 
spectrum; ONDs, other neurological disorders; Qalb, cerebrospinal fluid/serum 
quotients of albumin. 
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Table 2. CSF and serum MMP, TIMP, and cytokine profiles of NMO, MS, and OND patients 
bMMPs/TIMPs/Cytokines (pg/mL) 
NMO  
(n = 29) 
MS 
(n = 29) 
ONDs 
(n = 27) 
P value 
 
NMO vs.  
MS 
NMO vs. 
ONDs 
MS vs. 
ONDs 
CSF MMPs MMP-1  
a114 
(236) 
288 (174) 114 (236) 0.120 0.678 0.063 
  
MMP-2 
184189 
(110537) 
140916 
(31838) 
149457 
(47649) 
0.005* 0.022* 0.451 
  
MMP-3 
1096 
(1263) 
1096 
(962) 
442 (654) 0.730 0.115 0.119 
  
MMP-7 
1242 
(430) 
1242 
(571) 
954 (509) 0.404 0.069 0.037 
  
MMP-8 
2802 
(897) 
2605 
(618) 
2858 
(578) 
0.888 0.476 0.222 
  
MMP-9 508 (351) 686 (354) 508 (289) 0.943 0.021 0.031 
  
MMP-10 972 (507) 715 (257) 972 (323) 0.195 0.254 0.817 
  
MMP-12 
22.2 
(0.00) 
22.2 
(0.00) 
22.2 
(0.00) 
0.161 0.492 1.000 
  
MMP-13 264 (147) 338 (75) 192 (147) 0.066 0.317 0.009* 
 
TIMPs TIMP-1  
194900 
(159162) 
140276 
(48062) 
150459 
(63917) 
0.002* 0.010* 0.757 
  
TIMP-2 
64201 
(15523) 
69254 
(20849) 
64793 
(17531) 
0.055 0.773 0.037 
  
TIMP-3 
99.4 
(0.00) 
99.4 
(0.00) 
99.4 
(0.00) 
0.654 1.000 0.612 
  
TIMP-4 
72.4 
(0.00) 
72.4 
(0.00) 
72.4 
(0.00) 
0.082 - 0.237 
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Cytokines IL-1β 
0.49 
(0.00) 
0.49 
(0.00) 
0.49 
(0.00) 
0.418 0.112 0.492 
  
IL-4 
9.40 
(0.00) 
9.40 
(0.00) 
9.40 
(0.00) 
- - - 
  
IL-6 
89.3 
(737.7) 
59.1 
(43.4) 
46.9 
(52.8) 
0.013* 0.010* 0.848 
  
IL-10 
1.57 
(31.52) 
1.57 
(11.03) 
1.57 
(11.03) 
0.150 0.484 0.547 
  
IL-17A 
2.96 
(12.15) 
40.58 
(43.08) 
2.96 
(15.16) 
<0.001* 0.780 <0.001* 
  
IL-17F 
18.33 
(0.00) 
18.33 
(0.00) 
18.33 
(0.00) 
0.326 1.000 0.482 
  
IL-21  
142 
(0.00) 
141.70 
(0.00) 
141.70 
(0.00) 
- - - 
  
IL-22 
9.37 
(0.00) 
9.37 
(0.00) 
9.37 
(0.00) 
0.421 0.503 0.858 
  
IL-23 
13.0 
(13.8) 
13.0 
(43.1) 
13.0 
(0.00) 
0.668 0.328 0.196 
  
IL-25  
2.18 
(0.00) 
2.18 
(0.00) 
2.18 
(0.00) 
0.169 1.000 0.286 
  
IL-31 
23.5 
(0.00) 
23.5 
(0.00) 
23.5 
(0.00) 
- - - 
  
IL-33 
93.4 
(29.7) 
89.7 
(29.7) 
97.0 
(18.4) 
0.981 0.655 0.504 
  
IFN-γ 
15.7 
(0.00) 
15.7 
(0.00) 
15.7 
(0.00) 
0.977 0.479 0.598 
  
TNF-α 
9.28 
(5.64) 
6.83 
(3.39) 
7.66 
(4.96) 
0.068 0.389 0.436 
  
MMP-2/TIMP-2 
2.77 
(1.56) 
2.00 
(0.66) 
2.28 
(0.62) 
<0.001* 0.01* 0.016* 
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MMP-9/TIMP-1  
0.0031 
(0.0028) 
0.0038 
(0.0035) 
0.0032 
(0.0032) 
0.084 0.745 0.221 
Serum MMPs MMP-2 
127110 
(49016) 
123155 
(44039) 
136748 
(65846) 
0.243 0.742 0.195 
  
MMP-9 
104453 
(138410) 
105913 
(156113) 
101562 
(179452) 
0.731 0.880 0.883 
  
MMP-13 
86.1 
(82.5) 
44.5 
(118.7) 
44.5 
(77.7) 
0.187 0.219 0.927 
 
TIMPs TIMP-1 
577313 
(974497) 
43203 
(467722) 
400274 
(1015322) 
0.061 0.711 0.177 
 
Cytokines IL-6 
2.32 
(0.00) 
2.32 
(0.00) 
2.32 
(82.51) 
0.892 0.266 0.321 
  
IL-17A 
3.22 
(0.00) 
3.22 
(0.00) 
3.22 
(0.00) 
0.082 0.799 0.228 
aData are presented as median (interquartile range within parentheses). 
bCSF, cerebrospinal fluid; IFN, interferon; IL, interleukin; MMP, matrix metalloproteinase; MS, multiple 
sclerosis; NMO, neuromyelitis optica; ONDs, other neurological disorders; TIMP, tiss ue inhibitors of 
metalloproteinases; TNF, tumor necrosis factor. 
* Statistically significant after multiple comparison adjustment. 
 Table 3. Correlation between Qalb and levels of CSF MMPs, TIMPs, and cytokines in NMO 
patients. 
aCSF 
MMPs 
Spearman's rank 
correlation 
coefficient (ρ)  P value  
 CSF 
cytokines 
Spearman's rank 
correlation 
coefficient (ρ)  P value 
MMP-1 −0.446  0.022  
 
IL-1β 0.382  0.054  
MMP-2 0.753  <0.0001 
 
IL-4 N.A. N.A. 
MMP-3 0.407  0.039  
 
IL-6 0.450  0.021  
MMP-7 0.580  0.002  
 
IL-10 0.529  0.006  
MMP-8 −0.267  0.188  
 
IL-17A 0.157  0.444  
MMP-9 0.087  0.673  
 
IL-17F 0.253  0.212  
MMP-10 0.531  0.005  
 
IL-21 N.A. N.A. 
MMP-12 −0.023  0.912  
 
IL-22 0.157  0.443  
MMP-13 −0.051  0.806  
 
IL-23 −0.229  0.260  
TIMP-1 0.604  0.001  
 
IL-25 0.199  0.330  
TIMP-2 0.243  0.232  
 
IL-31 N.A. N.A. 
TIMP-3 0.000  1.000  
 
IL-33 -0.142  0.491  
TIMP-4 N.A. N.A. 
 
IFN-γ -0.155  0.451  
    
TNF-α 0.552  0.004  
aCSF, cerebrospinal fluid; IFN, interferon; IL, interleukin; MMP, matrix metalloproteinase; N.A., 
not available; NMO, neuromyelitis optica; TIMP, tissue inhibitors of metalloproteinases; TNF, 
tumor necrosis factor; Qalb, cerebrospinal fluid/serum quotients of albumin. 
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